Clinical studies showed that serum biomarkers, especially ALT levels, are sensitive in the detection of NAFLD and have also been associated with an increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease [16, 25]. This evidence concerns the gene GPT and cardiovascular disorder.